# Integra LifeSciences to acquire Acclarent for $280M

Integra LifeSciences entered a definitive agreement to acquire Acclarent from Ethicon (Johnson & Johnson) for $275 million in cash at closing plus up to $5 million upon regulatory milestones. Acclarent is an ENT device company headquartered in Irvine, California.

- Type: Acquisition
- Announced: 2023-12-13
- Where: Irvine, California, United States
- Value: $280.0M
- Status: announced
- Products: balloon technologies for sinus dilation, eustachian tube dilation, surgical navigation systems
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Johnson & Johnson](https://endata.com/companies/9845.md) (partner)
- [Integra LifeSciences](https://endata.com/companies/21365.md) (acquirer)
- [Ethicon](https://endata.com/companies/22274.md) (partner)
- [Acclarent](https://endata.com/companies/74397.md) (target)

## Sources

- [investor.integralife.com](https://investor.integralife.com/news-releases/news-release-details/integra-lifesciences-announces-definitive-agreement-acquire-1), 2023-12-13: "This acquisition presents Integra with a rare opportunity to become a key player in the ENT segment."
- [morganlewis.com](https://www.morganlewis.com/news/2023/12/morgan-lewis-represents-integra-lifesciences-in-acquisition-of-acclarent-from-johnson-johnson), 2023-12-13: "Morgan Lewis advised Integra LifeSciences Holdings Corporation in a definitive agreement to acquire Acclarent from Ethicon, a Johnson & Johnson company, for $275 million in cash at closing."
- [vcbeathealth.com](https://www.vcbeathealth.com/article/18180), 2023-12-15: "Integra Lifesciences, a leader in tissue repair, announced that the company has reached an agreement and is preparing to $275 million in cash to acquire Acclarent, a subsidiary of Johnson & Johnson focused on ear, nose, and throat."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.